welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
study id #: NCT01483144
condition: Familial Adenomatous Polyposis
status: completed
purpose:The purpose of this randomized, double-blind, Phase III trial is to determine if the combination of eflornithine plus sulindac is superior to sulindac or eflornithine as single agents in delaying time to the first occurrence of any FAP-related event. This includes:
1) FAP related disease progression indicating the need for excisional intervention involving the colon, rectum, pouch, duodenum and/or
2) clinically important events which includes progression to more advanced duodenal polyposis, cancer or death.
intervention:
Drug: Eflornithine plus Sulindac
Drug: Eflornithine and Placebo
Drug: Sulindac and Placebo
expertly curated content related to this topic
-
Ileostomy: A GuideIleostomy surgery is done for many diffe...
-
NIH-funded study shows sorafenib improves progression-free survival for patients with rare sarcomasInterim results from a randomized clinic...
-
Thetis Pharmaceuticals Awarded Key Patent on HEALER TechnologyThetis Pharmaceuticals LLC, a privately-...
-
Procedure for Construction of an IPAAhttps://o.quizlet.com/jDNbvWUyQJxevMasMm...
-
Aspirin and Familial Adenomatous Polyposis: Coming Full CircleThis perspective discusses the clinical ...
-
Genetic Polymorphisms of Flavin Monooxygenase 3 in Sulindac-Induced Regression of Colorectal Adenomas in Familial Ad...Sulindac is a nonsteroidal antiinflammat...
-
Sulindac/Erlotinib Combo Tested in Patients with Familial Adenomatous PolyposisA lower duodenal polyp burden was seen a...